Keyphrases
Systemic Lupus Erythematosus
97%
Lupus
82%
Systemic Lupus Erythematosus Patient
54%
Peruvian
51%
Rheumatology
43%
Autoimmune Disease
35%
Rheumatic Diseases
33%
COVID-19
31%
COVID-19 Vaccination
27%
Disease Activity
26%
Health-related Quality of Life
25%
Systemic Lupus International Collaborating Clinics
25%
Damage Accrual
22%
Latin America (LATAM)
22%
Remission
21%
Confidence Interval
20%
Peru
18%
Living with
18%
Multi-ethnic
17%
American League
17%
Pan American
17%
American College of Rheumatology
17%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
17%
Latin American
17%
ANCA-associated Vasculitis
16%
Low Disease Activity
16%
COVID-19 Patients
16%
Idiopathic Inflammatory Myopathies
16%
Granulomatosis with Polyangiitis
15%
Systematic Literature Review
14%
Rheumatoid Arthritis
14%
Classification Criteria
13%
SLE Disease Activity Index (SLEDAI)
13%
Microscopic Polyangiitis
13%
Age at Diagnosis
13%
COVID-19 Outcomes
12%
Comorbidity
12%
Healthy Controls
12%
European League against Rheumatism (EULAR)
12%
Odds Ratio
11%
Clinical Features
11%
Vasculitis
11%
International Survey
11%
Damage Index
11%
Access to Care
11%
Frailty Index
11%
COVAD
11%
Zonulin
11%
Gut Permeability
11%
Inception Cohort
11%
Tertiary Care Hospital
11%
Patient Data
11%
Vaccine Safety
11%
OMERACT
11%
Disease Duration
10%
Rheumatologists
10%
Long-term Safety
10%
COVID-19 Severity
10%
Takayasu Arteritis
9%
Activity State
9%
Patient Health
8%
Adverse Events
8%
Multivariable
8%
Autoimmune Rheumatic Diseases
8%
Health Disparities
8%
Low-middle Income Countries
8%
Prednisone
8%
Multivariable Model
8%
Core Outcome Set
8%
United States
8%
Systemic Autoimmune Rheumatic Diseases
8%
Vaccine Hesitancy
8%
Disease Activity Score
7%
Disease Flare
7%
Non-genetic Factors
7%
Hazard Ratio
7%
Population Interventions
7%
Giant Cell Arteritis
7%
SLICC
6%
Autoantibodies
6%
Lima
6%
Epidemiology
6%
Brazil
6%
Environmental Factors
6%
Lupus Low Disease Activity State (LLDAS)
6%
Rheumatoid Arthritis Patients
6%
Healthcare Professionals
6%
Rituximab
6%
Hospitalization
6%
Symptom Duration
6%
Coronavirus Disease 2019 Vaccination
6%
Latin American Patient
6%
Breakthrough Infection
6%
Long COVID-19
6%
Physical Activity
6%
Health Care Use
6%
Socioeconomic Status
6%
Polymyalgia Rheumatica
5%
General Practitioners
5%
Comparative Analysis
5%
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Lupus Erythematosus
73%
Rheumatology
49%
COVID-19
39%
Disease Activity
32%
Rheumatic Disease
27%
ANCA Associated Vasculitis
22%
Disease
21%
Rheumatoid Arthritis
17%
Inflammatory Arthritis
17%
Autoimmune Disease
16%
Cross Sectional Study
14%
Prevalence
14%
Autoimmune Rheumatic Disease
14%
Vasculitis
13%
Quality of Life
13%
SLEDAI
12%
Granulomatosis with Polyangiitis
11%
Clinical Feature
11%
Myositis
11%
COVID-19 Vaccination
11%
Vaccine Hesitancy
11%
Frailty Index
11%
Microscopic Polyangiitis
11%
Systematic Review
9%
Disease Duration
8%
Takayasu's Arteritis
8%
Health Care Cost
8%
Disease Exacerbation
8%
Glucocorticoid
7%
Health Care
7%
Lupus Vulgaris
7%
Infection
7%
Low and Middle Income Countries
6%
Prednisone
6%
Immunosuppressant
6%
Health Disparity
6%
Giant-Cell Arteritis
6%
COVID-19 Vaccine
6%
Cohort Effect
6%
Rituximab
6%
Patient Referral
6%
Odds Ratio
6%
Physical Activity
6%
Personal Experience
6%
Clinician
6%
Comorbidity
5%
Adverse Event
5%
Acute Respiratory Distress Syndrome
5%
Booster Dose
5%
Herd Immunity
5%
Clinimetrics
5%
Evans Syndrome
5%
Hemolytic Anemia
5%
Metabolic Syndrome
5%
Exercise
5%
Gut
5%
Patient-Data
5%
Zonulin
5%
IgG4-Related Disease
5%
Medicine
5%
Immunomodulation
5%
Tertiary Care
5%
Self Concept
5%
Cardiovascular Risk
5%
Systemic Vasculitis
5%
Mental Capacity
5%
Insulin Dependent Diabetes Mellitus
5%
Type 1 Diabetes
5%
Antiphospholipid Antibody
5%
Cognitive Defect
5%
Photosensitivity
5%
Lean Body Weight
5%
Lupus Nephritis
5%
Drug Therapy
5%